View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Tűzoltó u. 58., 1094

Absztrakt

A neuropeptid Y és a P anyag olyan neuropeptidek, amelyek fontos szerepet játszanak az immunsejtek működésében és a gyulladásos folyamatok fenntartásában és eliminálásában. Hepatitisben mindkét neuropeptidet tartalmazó idegrost mennyisége megnövekszik, a neuropeptid Y immunreaktív rostok növekedése szignifikáns. Számos lymphocytában és hízósejtben szintén neuropeptid Y és a P anyag mutatható ki. Gyakran figyelhető meg közeli kapcsolat (kevesebb mint 1 µm) a neuropeptid Y immunreaktív idegrostok és a neuropeptid Y pozitív immunsejtek között. Az immunsejtek egy részében tumornekrózis-faktor-α és nukleáris faktor kappa-B-jelölődés is megfigyelhető. Néhány P anyagot tartalmazó immunsejtben kolokalizációban figyelhető meg a tumornekrózis-faktor-α. Feltételezhető, hogy hepatitisben az idegrostokból és immunsejtekből felszabaduló neuropeptid Y és P anyag részt vesz a gyulladásos folyamatokban és azok eliminálásában. Orv. Hetil., 2015, 156(47), 1892–1897.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Elenkov, I. J., Wilder, R. L., Bakalov, V. K., et al.: IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab., 2001, 86(10), 4933–4938.

  • 2

    Bellinger, D. L., Millar, B. A., Perez, S., et al.: Sympathetic modulation of immunity: relevance to disease. Cell. Immunol., 2008, 252(1–2), 27–56.

  • 3

    Fehér, E., Batbayar, B., Vér, Á., et al.: Changes of the different neuropeptide containing nerve fibres and immunocells in the diabetic rat’s alimentary tract. Ann. N. Y. Acad. Sci., 2006, 1084, 280–295.

  • 4

    Lorton, D., Lubahn, C., Lindquist, C. A., et al.: Changes in the density and distribution of sympathetic nerves in spleens from Lewis rats with adjuvant-induced arthritis suggest that an injury and sprouting response occurs. J. Comp. Neurol., 2005, 489(2), 260–273.

  • 5

    Weinstock, J. V.: Substance P and the regulation of inflammation in infections and inflammatory bowel disease. Acta Physiol. (Oxf.), 2015, 213(2), 453–461.

  • 6

    Ho, W. Z., Kaufmann, D., Uvaydova, M., et al.: Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J. Neuroimmunol., 1996, 71(1–2), 73–80.

  • 7

    Sipos, G., Sipos, P., Altdorfer, K., et al.: Correlation and immunolocalization of substance P nerve fibers and activated immune cells in human chronic gastritis. Anat. Rec., 2008, 291(9), 1140–1148.

  • 8

    O’Connor, T. M., O’Connell, J., O’Brien, D. I., et al.: The role of substance P in inflammatory disease. J. Cell. Physiol., 2004, 201(2), 167–180.

  • 9

    Ansel, J. C., Brown, J. R., Payan, D. G., et al.: Substance P selectively activates TNF-alpha gene expression in murine mast cells. J. Immunol., 1993, 150(10), 4478–4485.

  • 10

    Lai, J. P., Douglas, S. D., Ho, W. Z.: Human lymphocytes express substance P and its receptor. J. Neuroimmunol., 1998, 86(1), 80–86.

  • 11

    Bedoui, S., Kawamura, N., Straub, R. H., et al.: Relevance of neuropeptide Y for the neuroimmune crosstalk. J. Neuroimmunol., 2003, 134(1–2), 1–11.

  • 12

    De la Fuente, M., Del Río, M., Medina, S.: Changes with aging in the modulation by neuropeptide Y of murine peritoneal macrophage functions. J. Neuroimmunol., 2001, 116(2), 156–167.

  • 13

    Dimitrijević, M., Stanojević, S., Vujić, V., et al.: Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage fuctions in vitro: counter regulation through Y1 and Y2/5 receptors. Regul. Pept., 2005, 124(1–3), 163–172.

  • 14

    Fehér, E., Pongor, É., Altdorfer, K., et al.: Neuroimmumodulation in human autoimmune liver disease. Cell Tissue Res., 2013, 354(2), 543–550.

  • 15

    Kawamura, N., Tamura, H., Obana, S.: Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation, 1998, 5(1–2), 9–15.

  • 16

    Leceta, J., Martínez, C., Delgado, M., et al.: Expression of vasoactive intestinal polypeptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol., 1996, 6(1), 29–36.

  • 17

    Fehér, E., Altdorfer, K., Bagaméri, G., et al.: Neuroimmune interactions in experimental colitis. Neuroimmunomodulation, 2001, 9(5), 247–255.

  • 18

    Rakonczay, Z. Jr., Hegyi, P., Takács, T., et al.: The role of NF-κB activation in the pathogenesis of acute pancreatitis. Gut, 2008, 57(2), 259–267.

  • 19

    Chakraborty, J. B.., Mann, D. A.: NF-κB signalling: embracing complexity to achieve translation. J. Hepatol., 2010, 52(2), 285–291.

  • 20

    Pongor, É., Altdorfer, K., Fehér, E.: Colocalization of substance P with tumor necrosis factor-α in the lymphocytes and mast cells in gastritis in experimental rats. Inflamm. Res., 2011, 60(2), 163–168.

  • 21

    D’Mello, C., Swain, M. G.: Liver-brain interactions in inflammatory liver diseases: implications for fatigue and mood disorders. Brain Behav. Immun., 2014, 35, 9–20.

  • 22

    Dienes, H. P., Hütteroth, T., Hess, G., et al.: Immunoelectron observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology, 1987, 7(6), 1317–1325.

  • 23

    Tiegs, G. T.: NKT cells and NK cells in an experimental model of autoimmune hepatitis. In: Gershwin, M. E., Vierling, J. M., Manns, M. P. (eds.): Textbook on liver immunology. Hanley and Belfus, Philadelphia, 2003.

  • 24

    Lohse, A. W., Weiler-Normann, C., Tiegs, G.: Immune-mediated liver injury. J. Hepatol., 2010, 52(1), 136–144.

  • 25

    Mühlen, K. A., Schümann, J., Wittke, F., et al.: NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J. Immunol., 2004, 172(5), 3034–3041.

  • 26

    Bang, R., Biburger, M., Neuhuber, W. L., et al.: Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage. J. Pharmacol. Exp. Ther., 2004, 308(3), 1174–1180.

  • 27

    Kataeva, G., Agro, A., Stanisz, A. M.: Substance-P-mediated intestinal inflammation: inhibitory effects of CP 96,345 and SMS 201-995. Neuroimmunomodulation, 1994, 1(6), 350–356.

  • 28

    Sonea, I. M., Palmer, M. V., Akili, D., et al.: Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin. Diagn. Lab. Immunol., 2002, 9(2), 333–340.

  • 29

    Batbayar, B., Nagy, G., Kövesi, G., et al.: Morphological basis of sensory neuropathy and neuroimmunomodulation in minor salivary glands of patients with Sjögren’s syndrome. Arch. Oral Biol., 2004, 49(7), 529–538.

  • 30

    Sipos, G., Altdorfer, K., Pongor, É., et al.: Neuroimmune link in the mucosa of chronic gastritis with Helicobacter pylori infection. Dig. Dis. Sci., 2006, 51(10), 1810–1817.

  • 31

    Bedoui, S., Kromer, A., Gebhardt, T., et al.: Neuropeptide Y receptor-specifically modulates human neutrophil function. J. Neuroimmunol., 2008, 195(1–2), 88–95.

  • 32

    Zukowska, Z., Pons, J., Lee, E. W., et al.: Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can. J. Physiol. Pharmacol., 2003, 81(2), 89–94.

  • 33

    Dimitrijević, M., Stanojević, S., Mićić, L., et al.: Neuropeptide Y (NPY) modulates oxidative burst and nitric oxide production in carrageenan-elicited granulocytes from rat air pouch. Peptides, 2006, 27(12), 3208–3215.

  • 34

    Farzi, A., Reichmann, F., Holzer, P.: The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol. (Oxf.), 2015, 213(3), 603–627.

  • 35

    Dimitrijević, M., Stanojević, S., Mitić, K., et al.: The anti-inflammatory effect of neuropeptide Y (NPY) in rats is dependent on dipeptidyl peptidase 4 (DP4) activity and age. Peptides, 2008, 29(12), 2179–2187.

  • 36

    Wheway, J., Herzog, H., Mackay, F.: NPY and receptors in immune and inflammatory diseases. Curr. Top. Med. Chem., 2007, 7(17), 1743–1752.